Executive Report-4

The intent of Bottle Recall initially was to be able to allow patients take home medication and to insure that methadone is not diverted to the streets. However, methadone programs have been giving patients take home medication for years without a serious methadone diversion problem. Furthermore numerous studies have demonstrated that methadone is not a…

Part 828.11 New York Title 17 NYCRR Length of Treatment: a. If a patient has been admitted for less than 3 months daily clinic visits are required unless the program is open only 6 days. b. More than 3 months but less than 2 years 3 visits a week are required. c. More then 2…

Membership Application Name:   _______________________________________________________   Mr. ___  Ms. ___  Dr. ___ Organization:  __________________________________________________________________________ Title:  _____________________________________________  Degree(s):  ________________________ Address:  _____________________________________________________________________________ Address:  _____________________________________________________________________________ City:   __________________________________   State:   ____________   Postal Code:   _____________ Email:  ______________________________________  Country:   ________________________________ Home Phone: (____)___________________________   Work Phone:  (____)_______________________ Alternate Phone:  (____)________________________   Fax:  (____)______________________________ If you have email may we send you bulletin alerts electronically. (This will get bulletin alerts to you quicker than usual mail)   Yes  _____   No _____ Types of Membership $_______ Individual Membership   Dues: $25 a…

Issues To Focus On LAAM Manufacture to Be Discontinued August 23, 2003 Washington, D.C. Roxanne the manufacturer of LAAM has informed the FDA that manufacture of the medication is being discontinued. Distribution will continue until the inventory is depleted. Roxanne estimates this to be in early January 2004. The reason for the action is the…

 Vol. 66, No. 11 / Wednesday, January 17, 2001 / Rules and Regulations (i)                 Unsupervised or take-home use.   To limit the potential for diversion of opioid agonist treatment medications to the illicit market, opioid agonist treatment medications dispensed to patients for unsupervised use shall be subject to the following requirements.   (1)   Any patient…

FDA Warns About Orlaam T01-15 Print Media: 301-827-6242 April 20, 2001 Broadcast Media: 301-827-3434   Consumer Inquiries: 888-INFO-FDA The U.S. Food and Drug Administration (FDA) issued a new warning about health risks associated with levomethadyl acetate HC, a.k.a. Orlaam, a drug used to treat opiate addiction. FDA Announces Labeling Changes Following Cardiac Adverse Events With…